In this open-label , randomised , phase 3 trial , eligible patients were 18 years , chemonave , East Asian , light ex-smokers/never-smokers with advanced non-squamous non-small cell lung cancer , an Eastern Cooperative Oncology Group ( ECOG ) performance status 0-1 and unknown epidermal growth factor receptor ( EGFR ) mutation status who enrolled at 12 sites in Asia .